Application

Detect AMACR using this Anti-AMACR Antibody validated for use in WB, IH(P).

Western blot: 1:500

Immunohistochemistry: 1:100 in an ABC method. An incubation period of 30 minutes at room temperature is suggested. Formalin fixed paraffin embedded tissue sections require high temperature antigen unmasking with 10 mM citrate buffer, pH 6.0 prior to immunostaining.

Optimal working dilutions must be determined by end user.

General description

Prostate-specific antigen (PSA) screening for prostate cancer is now widespread in the United States among men of all ages. However PSA has limited specificity because benign disease, including prostatic enlargement and inflammation, can increase PSA levels. Thus, a more specific prostate cancer markers is needed. One such potential marker is AMACR, an enzyme that is involved in peroxisomal beta-oxidation of dietary branched-chain fatty acids. Recent studies have shown that, compared with expression in normal or benign prostate epithelium, AMACR is consistently overexpressed in prostate cancer epithelium, making it a specific marker for cancer cells within the prostate gland. Furthermore, overexpression of AMACR may increase the risk of prostate cancer because its expression is increased in premalignant lesions (prostatic intraepithelial neoplasia).

Immunogen

Synthetic human AMACR peptide.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

Peptide affinity purified antibody. Liquid in PBS, with 0.02% sodium azide as a preservative.

Specificity

Recognizes human AMACR (alpha-methylacyl-CoA racemase).

Storage and Stability

Maintain at 2-8°C in undiluted aliquots for 3 months or at -20°C for up to one year from date of receipt. Avoid repeated freeze-thaw cycles.